Literature DB >> 24331839

Immunohistochemical study of 36 cases of pulmonary sarcomatoid carcinoma--sensitivity of TTF-1 is superior to napsin.

Simone B S P Terra1, Marie Christine Aubry1, Eunhee S Yi1, Jennifer M Boland2.   

Abstract

Immunohistochemistry is often used to distinguish pulmonary sarcomatoid carcinoma from morphologic mimics. Napsin-A is a pulmonary adenocarcinoma marker, but literature on expression in sarcomatoid carcinoma is limited. Thirty-six cases of sarcomatoid carcinoma were stained for napsin, TTF-1, Oscar, CAM5.2, AE1/AE3, desmin, SMA, S-100, CK5/6, calretinin, D2-40, and WT1. Patients were 24 men and 12 women (mean, 70 years; range, 46-93). There were 27 pleomorphic carcinomas, 5 spindle cell carcinomas, 3 carcinosarcomas, and 1 giant cell carcinoma. Cases were positive for at least 1 keratin: AE1/3 was positive in all 36 cases; Oscar, in 34 cases (94%); and CAM5.2, in 32 cases (89%, weaker/more focal). Napsin was positive in 14 cases (39%): 8 diffuse, 3 focal, and 3 rare cells. TTF-1 was positive in 22 cases (61%): 15 diffuse, 3 focal, and 4 rare cells. No cases were napsin positive and negative for TTF-1. Variable staining for mesothelial markers was observed, including positivity for calretinin (12 cases, 33%), WT1 (6 cases, 17%), D2-40 (5 cases, 14%), and CK5/6 (9 cases, 25%). Mesenchymal markers were also sometimes positive (usually focal), including S-100 (4 cases, 11%), desmin (4 cases, 11%), and SMA (7 cases, 19%, 1 diffuse). In conclusion, TTF-1 is more sensitive than napsin for detection of sarcomatoid carcinoma, and no cases were positive for napsin but negative for TTF-1. CAM5.2 is less sensitive than AE1/AE3 and Oscar. Use of a thoughtful immunohistochemical panel is important in the evaluation of sarcomatoid carcinoma because mesothelial and mesenchymal markers can be expressed.
© 2014.

Entities:  

Keywords:  Lung sarcomatoid carcinoma; Napsin; TTF-1

Mesh:

Substances:

Year:  2013        PMID: 24331839     DOI: 10.1016/j.humpath.2013.09.005

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma.

Authors:  Erin Schenk; Jennifer Boland; Aaron Mansfield; Marie Christine Aubry; Allan Dietz
Journal:  Med Oncol       Date:  2017-07-15       Impact factor: 3.064

2.  Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.

Authors:  Simone Bsp Terra; Jin S Jang; Lintao Bi; Benjamin R Kipp; Jin Jen; Eunhee S Yi; Jennifer M Boland
Journal:  Mod Pathol       Date:  2016-05-13       Impact factor: 7.842

3.  Definitive Chemoradiotherapy for Advanced Pulmonary Sarcomatoid Carcinoma.

Authors:  Kazuya Takeda; Haruo Matsushita; Masaki Kubozono; Takaya Tanabe; Yojiro Ishikawa; Takaya Yamamoto; Maiko Kozumi; Noriyoshi Takahashi; Yu Katagiri; Shun Tasaka; Katsuya Fukui; Ken Takeda; Fumiyoshi Fujishima; Masakazu Ichinose; Keiichi Jingu
Journal:  Intern Med       Date:  2016-11-15       Impact factor: 1.271

4.  Pulmonary sarcomatoid carcinoma mimicking pleural mesothelioma: A case report.

Authors:  Le Wang; Jing Zhang; Xing Chen; Maoli Liang; Shuo Li; Wei Zhou; Jie Cao
Journal:  Medicine (Baltimore)       Date:  2021-11-12       Impact factor: 1.817

Review 5.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

6.  An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.

Authors:  Sonja Klebe; Adam Swalling; Lisa Jonavicius; Douglas W Henderson
Journal:  J Clin Pathol       Date:  2015-08-17       Impact factor: 3.411

7.  Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait.

Authors:  Ryan W Huey; Shalini Makawita; Lianchun Xiao; Aurelio Matamoros; Jeannelyn S Estrella; Michael J Overman; Gauri R Varadhachary; Kanwal Raghav
Journal:  BMC Cancer       Date:  2019-10-17       Impact factor: 4.430

8.  A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.

Authors:  Kosuke Sawatari; Motohiro Izumi; Risa Sone; Tsuyoshi Hattori; Akira Sugimoto; Yosuke Eguchi; Takashi Mamoto
Journal:  Respir Med Case Rep       Date:  2022-01-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.